The Chemours Company
NYSE:CC
18.48 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 6,027 | 6,794 | 6,345 | 4,969 | 5,526 | 6,638 | 6,183 | 5,400 | 5,717 | 6,432 | 6,859 | 7,365 | 7,972 |
| Cost of Revenue
| 4,716 | 5,178 | 4,964 | 3,902 | 4,463 | 4,667 | 4,429 | 4,290 | 4,762 | 5,072 | 5,395 | 5,014 | 5,375 |
| Gross Profit
| 1,311 | 1,616 | 1,381 | 1,067 | 1,063 | 1,971 | 1,754 | 1,110 | 955 | 1,360 | 1,464 | 2,351 | 2,597 |
| Gross Profit Ratio
| 0.218 | 0.238 | 0.218 | 0.215 | 0.192 | 0.297 | 0.284 | 0.206 | 0.167 | 0.211 | 0.213 | 0.319 | 0.326 |
| Reseach & Development Expenses
| 108 | 118 | 107 | 93 | 80 | 82 | 80 | 80 | 97 | 143 | 164 | 145 | 135 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 657 | 602 | 934 | 632 | 685 | 768 | 747 | 731 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 1,290 | 710 | 592 | 527 | 548 | 657 | 602 | 934 | 632 | 685 | 768 | 747 | 731 |
| Other Expenses
| 19 | 70 | 163 | 39 | -293 | 162 | 79 | 247 | 44 | 45 | 48 | 42 | 55 |
| Operating Expenses
| 1,398 | 828 | 699 | 620 | 628 | 739 | 682 | 1,014 | 729 | 828 | 932 | 892 | 866 |
| Operating Income
| -87 | 913 | 888 | 509 | 171 | 1,232 | 1,072 | 96 | 226 | 532 | 532 | 1,459 | 1,731 |
| Operating Income Ratio
| -0.014 | 0.134 | 0.14 | 0.102 | 0.031 | 0.186 | 0.173 | 0.018 | 0.04 | 0.083 | 0.078 | 0.198 | 0.217 |
| Total Other Income Expenses Net
| -231 | -172 | -212 | -330 | -295 | 118 | 55 | 106 | -282 | 18 | 44 | 26 | 176 |
| Income Before Tax
| -318 | 741 | 676 | 179 | -124 | 1,155 | 912 | -11 | -188 | 550 | 576 | 1,485 | 1,907 |
| Income Before Tax Ratio
| -0.053 | 0.109 | 0.107 | 0.036 | -0.022 | 0.174 | 0.148 | -0.002 | -0.033 | 0.086 | 0.084 | 0.202 | 0.239 |
| Income Tax Expense
| -81 | 163 | 68 | -40 | -72 | 159 | 165 | -18 | -98 | 149 | 152 | 427 | 474 |
| Net Income
| -238 | 578 | 608 | 219 | -52 | 995 | 746 | 7 | -90 | 400 | 423 | 1,057 | 1,431 |
| Net Income Ratio
| -0.039 | 0.085 | 0.096 | 0.044 | -0.009 | 0.15 | 0.121 | 0.001 | -0.016 | 0.062 | 0.062 | 0.144 | 0.18 |
| EPS
| -1.6 | 3.72 | 3.69 | 1.33 | -0.32 | 5.62 | 4.04 | 0.04 | -0.5 | 2.21 | 2.33 | 5.83 | 7.89 |
| EPS Diluted
| -1.6 | 3.65 | 3.6 | 1.32 | -0.32 | 5.45 | 3.91 | 0.04 | -0.5 | 2.19 | 2.31 | 5.78 | 7.83 |
| EBITDA
| 220 | 1,204 | 1,205 | 829 | 482 | 1,721 | 1,457 | 656 | 559 | 836 | 826 | 1,766 | 1,926 |
| EBITDA Ratio
| 0.037 | 0.177 | 0.19 | 0.167 | 0.087 | 0.259 | 0.236 | 0.121 | 0.098 | 0.13 | 0.12 | 0.24 | 0.242 |